In the shoes of Fabrice, R&D development engineer
Application design, development... Immersion in Diabeloop's "Platforms" team.
People first*
Diabeloop partners with patients: Since its creation, Diabeloop has been involving people living with Type 1 diabetes and their families. They have contributed to the development alongside engineers and healthcare professionals.
The ease of use and intuitive interfaces of personalized solutions developed by Diabeloop are really inspired by patients and their personal experiences.
The international launch of an independent young company
In November 2018, Diabeloop’s first medical device, DBLG1, was CE marked. We are working on commercializing, in Europe (France and Germany at first) and later in North America.
To support our international ambition and our Research and Development roadmap, we completed a Series B round of funding, setting a European fundraising record for therapeutic artificial intelligence.
Our latest news
Diabeloop strongly listens to patients advocates’ (#dedoc) voices
By sponsoring the #dedoc voices program, we contribute to make...
Elke volunteered at a Coronavirus drive-in testing station
What exactly is a drive-in testing station? How does it...
Reduce the heavy burden for people with diabetes
Diabeloop developed a self-learning algorithm that embeds therapeutic artificial intelligence, to automate Type 1 diabetes treatment. It is intended to relieve people affected by this chronic condition from having to make constant therapeutic decisions every day and night, and to allow them to live life without interruption.
The media specialized in diabetology cites Diabeloop as one of the technological innovations using AI for health.
Diabeloop opens a subsidiary in Germany
EIT Health supports Diabeloop's D4Kids project, an automated solution for the treatment of Type 1 diabetes adapted to children.
The information magazine for healthcare professionals provides an overview of closed-loop systems for T1D treatment.
Diabeloop announces the conclusion of an agreement with exclusive distribution with Terumo Corporation for DBLG1 Automated Insulin Delivery Solution in Japanese market
https://www.asianhhm.com/pressreleases/diabeloop-sa-and-terumo-corporation-enter-into-joint-development-agreement-with-exclusive-distribution-rightThey talk about us
The media specialized in diabetology cites Diabeloop as one of the technological innovations using AI for health.
Awards
French Tech 120
Start Up of the Year 2019 award
InnovEIT Award 2019
Awarding fundings in 2016-2017 and 2018-2019-2020
Trophée de l'Embarqué, Health Award
Born Global Award Start-up of the Year EY 2018
Jury Prize, Start-up of the Year SNITEM
Samsung Artificial Intelligence Award Vivatech 2018